WuXi Biologics intends to set up a biologics manufacturing facility in Singapore

Chinese biotech WuXi Biologics announced that it is to invest $60 million and hire approximately 150 employees to establish a state-of-the-art biologics manufacturing facility in Singapore. It will be the 10th global drug substance manufacturing facility of WuXi Biologics.

Headquartered in Wuxi city, Jiangsu province, China, WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.

This state-of-the-art “facility of the future” will be built upon the novel approach WuXi Biologics has pioneered deploying single-use bioreactors. It is also designed to be able to run continuous bioprocessing, a next generation manufacturing technology to be first implemented in Asia outside of China. A total of approximately 4,500 L bioreactor capacity will be installed with two 2,000 L traditional fed-batch and one 500 L perfusion based continuous processing. This facility will be able to handle both clinical and small volume commercial production. An early-stage bioprocess development lab will also be included.

The new manufacturing facility, supported by the Singapore Economic Development Board, is the first Wuxi Biologoverseas site in Asia and second site outside of China.

SOURCE: wuxi biologics
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.